PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board
PulseSight Therapeutics announced the formation of a Scientific and Clinical Advisory Board (SAB) composed of internationally recognized experts in ophthalmology from Europe, the US, and Australia with extensive experience in both fundamental and clinical research in retinal and macular diseases.
The SAB will be chaired by Prof. Frank G. Holz, Professor and Chair of the Department of Ophthalmology at the University of Bonn, Germany. Prof. Holz is globally respected for his contributions to the field of ophthalmology, particularly in retinal research.
Other members of the SAB include:
Prof. Francine Behar-Cohen, MD, PhD - Professor of Ophthalmology at Cochin Hospital, Paris, Director of Research at INSERM, and Professor at the University of Paris Cité, France. Prof. Behar-Cohen, who discovered and developed PulseSight’s core technology, also serves as a Board member and an observer.
Joshua Dunaief, MD, PhD - Adele Niessen Professor of Ophthalmology at The Perelman School of Medicine, University of Pennsylvania, PA, USA. Dr. Dunaief is recognized for his groundbreaking research in retinal degeneration.
Prof. Robyn Guymer AM - Deputy Director and Head of Macular Research at the Centre for Eye Research Australia (CERA), Melbourne, Australia, and Professor of Ophthalmology at Melbourne University. She is also a senior retinal specialist at the Royal Victorian Eye and Ear Hospital.
Prof. Eleonora Lad, MD, PhD - Vice Chair and Associate Professor of Ophthalmology, and Vice Chair of Clinical Research at the Duke Eye Center, NC, USA. Prof. Lad is noted for her expertise in clinical trials and innovative treatments for retinal diseases.
PulseSight’s lead program, PST-611, targeting geographic atrophy (GA), is on track to enter clinical trials by the end of 2024. The company’s second program, PST-809, focused on wet age-related macular degeneration (AMD), is in the late stages of preclinical IND-enabling studies.
“I am delighted to welcome these world-class seasoned experts as founding members of our SAB. Their depth and breadth of clinical and scientific expertise will bring invaluable contributions to our development plans as we navigate early clinical development," Judith Greciet, CEO of PulseSight Therapeutics, said in a company news release. "Their enthusiastic agreement to join the SAB underlines the interest in our innovative programs and reinforces our confidence that PST-611, followed by PST-809, have the potential to significantly change the prognostic of these highly disabling, difficult-to-treat diseases.”